Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indium-111-labeled Trillium compound
- Development stage
- Phase 1
- Lead developer
- Ratio Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Indium-111-labeled Trillium compound is a novel **radiopharmaceutical drug conjugate** developed by Ratio Therapeutics for the treatment of prostate cancer. This compound targets **prostate-specific membrane antigen (PSMA)**, which is overexpressed on prostate cancer cells, delivering the radioactive isotope indium-111 directly to PSMA-expressing tumors. The mechanism of action is based on targeted delivery of ionizing radiation, causing DNA damage and subsequent cell death in cancer cells. The compound is being studied both as a monotherapy and in combination with the cytoprotective agent PTI-122 to potentially reduce off-target toxicity. It is currently in early clinical development (Phase 0 trials) for metastatic prostate cancer[1][3][4][5][7].
- Other names
- PSMA-targeted indium-111-labeled Trillium compoundIn-111-labelled Trillium compoundIn111-labelled Trillium compoundIn 111-labelled Trillium compoundPSMA-targeted [In-111]-labeled Trillium compound
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on indium-111-labeled Trillium compound.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indium-111-labeled Trillium compound.